Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 5:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Lucentis (Treat and extend) Clear all
Completed No phase listed Observational

Seven Year Update of Macular Degeneration Patients

NCT01256827
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
55 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
12
States / cities
Beverly Hills, California • Los Angeles, California • Mountain View, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2013 · Synced Oct 2, 2026, 5:23 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration

NCT03038880
View directory record Official record
Conditions
Neovascularization, Choroidal, Macular Degeneration, Age-Related
Interventions
Faricimab, Ranibizumab, Sham Procedure
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
25
States / cities
Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 2, 2026, 5:23 AM EDT
Completed Phase 4 Interventional

Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD)

NCT01863199
View directory record Official record
Conditions
Neovascular Age Related Macular Degeneration
Interventions
Lucentis (Treat and extend), Lucentis every 4 weeks, Lucentis every 12 weeks
Drug
Lead sponsor
Retinal Consultants of Arizona
Other
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
4
States / cities
Gilbert, Arizona • Mesa, Arizona • Peoria, Arizona + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Oct 2, 2026, 5:23 AM EDT
Terminated Phase 3 Interventional Results available

OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)

NCT04757610
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
2.0 mg OPT-302, 0.5 mg ranibizumab, Sham
Biological · Procedure
Lead sponsor
Opthea Limited
Industry
Eligibility
50 Years and older
Enrollment
986 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
76
States / cities
Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 67 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Oct 2, 2026, 5:23 AM EDT
Completed Phase 3 Interventional Results available

Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab

NCT01748292
View directory record Official record
Conditions
Macular Degeneration
Interventions
0.5 mg ranibizumab
Drug
Lead sponsor
Charles C Wykoff, PhD, MD
Other
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
4
States / cities
West Columbia, South Carolina • Houston, Texas • Katy, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Oct 2, 2026, 5:23 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Safety and Efficacy Trial of a Treat and Extend Protocol Using Ranibizumab With and Without Laser Photocoagulation for Diabetic Macular Edema

NCT01934556
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Ranibizumab 0.3 mg intravitreal injection, Guided Laser Photocoagulation
Drug · Device
Lead sponsor
Palmetto Retina Center, LLC
Other
Eligibility
18 Years to 100 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
Beverly Hills, California • West Columbia, South Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 2, 2026, 5:23 AM EDT
Completed Phase 2 Interventional Results available

Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy.

NCT02222610
View directory record Official record
Conditions
Radiation Retinopathy
Interventions
0.5 mg ranibizumab, Targeted Retinal Photocoagulation (TRP)
Drug · Procedure
Lead sponsor
Greater Houston Retina Research
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
4
States / cities
Dallas, Texas • Houston, Texas • Katy, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Oct 2, 2026, 5:23 AM EDT
Completed Phase 3 Interventional Results available

Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion

NCT01198327
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
ranibizumab, Peripheral Laser
Drug · Other
Lead sponsor
Peter A Campochiaro, MD
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
6
States / cities
Beverly Hills, California • Sacremento, California • Augusta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Oct 2, 2026, 5:23 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of Ranibizumab for Diabetic Macular Edema

NCT01982435
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Ranibizumab
Drug
Lead sponsor
Justis Ehlers
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Cleveland, Ohio • Mayfield Heights, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Oct 2, 2026, 5:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema

NCT01476449
View directory record Official record
Conditions
Diabetic Retinopathy, Macular Edema
Interventions
Ranibizumab
Drug
Lead sponsor
Retina Vitreous Associates of Florida
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
2
States / cities
Clearwater, Florida • St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated May 17, 2019 · Synced Oct 2, 2026, 5:23 AM EDT
Recruiting Phase 3 Interventional

Extension Study for the Port Delivery System With Ranibizumab (Portal)

NCT03683251
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
PDS Implant with Ranibizumab 100 mg/mL
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
81
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 69 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 2, 2026, 5:23 AM EDT
Completed No phase listed Observational

Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Intravitreal Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients.

NCT01942213
View directory record Official record
Conditions
Neovascular Age Related Macular Degeneration
Interventions
Not listed
Lead sponsor
Prism Vision Group
Other
Eligibility
65 Years to 90 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Edison, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 1, 2016 · Synced Oct 2, 2026, 5:23 AM EDT
Withdrawn Phase 4 Interventional

Intravitreal Alfibercept for Center Involved DME Previously Managed With Intravitreal Ranibizumab

NCT03059277
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Intravitreal Aflibercept
Drug
Lead sponsor
Southeast Clinical Research Associates, LLC
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Charlotte, North Carolina • Statesville, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 2, 2026, 5:23 AM EDT
Completed Phase 3 Interventional Results available

Rainbow Extension Study

NCT02640664
View directory record Official record
Conditions
Retinopathy of Prematurity (ROP)
Interventions
Ranibizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Months to 5 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
9
States / cities
Sacramento, California • Aurora, Colorado • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Oct 2, 2026, 5:23 AM EDT